Fructose and liver function -is this behind nonalcoholic liver disease?

Current Opinion in Clinical Nutrition and Metabolic Care

Volumn 18, Issue 5, 2015, Pages 490-495

  Jin, Ran ^a   Vos, Miriam B ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Fructose; Hepatic steatosis; NAFLD; NASH; Sugar

Indexed keywords

C REACTIVE PROTEIN; FRUCTOSE; FRUCTOSE 1 PHOSPHATE; GAMMA GLUTAMYLTRANSFERASE; LOW DENSITY LIPOPROTEIN; REGULATOR PROTEIN; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TOLL LIKE RECEPTOR 4; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN; SWEETENING AGENT;

ACANTHOSIS NIGRICANS; CALORIC INTAKE; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DYSLIPIDEMIA; END STAGE LIVER DISEASE; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVITY; FATTY ACID OXIDATION; FATTY LIVER; FRUCTOSE METABOLISM; GLUCOSE INTAKE; GLYCEMIC LOAD; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; LIPID STORAGE; LIPOGENESIS; LIVER FUNCTION; LOW FAT DIET; MICROBIOME; NONALCOHOLIC FATTY LIVER; OBESITY; PARENTERAL NUTRITION; PATHOPHYSIOLOGY; PHENOTYPE; PROTEIN PHOSPHORYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; UPREGULATION; ADVERSE EFFECTS; DIET; INTESTINE FLORA; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE;

ADIPOSITY; DIET; FRUCTOSE; GASTROINTESTINAL MICROBIOME; HUMANS; LIPOGENESIS; LIVER; NON-ALCOHOLIC FATTY LIVER DISEASE; SWEETENING AGENTS;

EID: 84942805581     PISSN: 13631950     EISSN: 14736519     Source Type: Journal    
DOI: 10.1097/MCO.0000000000000203     Document Type: Review

References (43)

1. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341-1350.
2. Targher G, Byrne CD. Clinical review: Nonalcoholic fatty liver disease: A novel cardiometabolic risk factor for type 2 diabetes and its complications. J Clin Endocrinol Metab 2013; 98: 483-495.
3. Loomba R, Sanyal AJ. The global nafld epidemic. Nat Rev Gastroenterol Hepatol 2013; 10: 686-690.
4. Ng M, Fleming T, Robinson M, et al. Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: A systematic analysis for the global burden of disease study 2013. Lancet 2014; 384: 766-781.
5. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, et al. The natural history of nonalcoholic fatty liver disease in children: A follow-up study for up to 20 years. Gut 2009; 58: 1538-1544.
6. Welsh JA, Karpen S, Vos MB. Increasing prevalence of nonalcoholic fatty liver disease among united states adolescents, 1988-1994 to 2007-2010. J Pediatr 2013; 162: 496-500.
7. Lambert JE, Ramos-Roman MA, Browning JD, et al. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 2014; 146: 726-735.
8. Ouyang X, Cirillo P, Sautin Y, et al. Fructose consumption as a risk factor for nonalcoholic fatty liver disease. J Hepatol 2008; 48: 993-999.
9. Abdelmalek MF, Suzuki A, Guy C, et al. Increased fructose consumption is associated with fibrosis severity in patients with nonalcoholic fatty liver disease. Hepatology 2010; 51: 1961-1971.
10. O'Sullivan TA, Oddy WH, Bremner AP, et al. Lower fructose intake may help protect against development of nonalcoholic fatty liver in adolescents with obesity. J Pediatr Gastroenterol Nutr 2014; 58: 624-631.
11. Johnston RD, Stephenson MC, Crossland H, et al. No difference between high-fructose and high-glucose diets on liver triacylglycerol or biochemistry in healthy overweight men. Gastroenterology 2013; 145: 1016-1025.
12. Cox CL, Stanhope KL, Schwarz JM, et al. Consumption of fructose-but not glucose-sweetened beverages for 10 weeks increases circulating concentrations of uric acid, retinol binding protein-4, and gamma-glutamyl transferase activity in overweight/obese humans. Nutr Metab (Lond) 2012; 9: 68.
13. Silbernagel G, Machann J, Unmuth S, et al. Effects of 4-week very-highfructose/glucose diets on insulin sensitivity, visceral fat and intrahepatic lipids: An exploratory trial. Br J Nutr 2011; 106: 79-86.
14. Chiu S, Sievenpiper JL, de Souza RJ, et al. Effect of fructose on markers of nonalcoholic fatty liver disease (nafld) : A systematic review and meta-Analysis of controlled feeding trials. Eur J Clin Nutr 2014; 68: 416-423.
15. Chung M, Ma J, Patel K, et al. Fructose, high-fructose corn syrup, sucrose, and nonalcoholic fatty liver disease or indexes of liver health: A systematic review and meta-Analysis. Am J Clin Nutr 2014; 100: 833-849.
16. Jin R, Welsh JA, Le NA, et al. Dietary fructose reduction improves markers of cardiovascular disease risk in hispanic-American adolescents with NAFLD. Nutrients 2014; 6: 3187-3201.
17. Mager DR, Iniguez IR, Gilmour S, et al. The effect of a low fructose and low glycemic index/load (fragile) dietary intervention on indices of liver function, cardiometabolic risk factors, and body composition in children and adolescents with nonalcoholic fatty liver disease (NAFLD). JPEN J Parenter Enteral Nutr 2015; 39: 73-84.
18. Santoro N, Kursawe R, D'Adamo E, et al. A common variant in the patatin-like phospholipase 3 gene (PNPLA3) is associated with fatty liver disease in obese children and adolescents. Hepatology 2010; 52: 1281-1290.
19. Santoro N, Zhang CK, Zhao H, et al. Variant in the glucokinase regulatory protein (GCKR) gene is associated with fatty liver in obese children and adolescents. Hepatology 2012; 55: 781-789.
20. Lin YC, Chang PF, Chang MH, et al. Genetic variants in GCKR and PNPLA3 confer susceptibility to nonalcoholic fatty liver disease in obese individuals. Am J Clin Nutr 2014; 99: 869-874.
21. Goran MI, Walker R, Allayee H. Genetic-related and carbohydrate-related factors affecting liver fat accumulation. Curr Opin Clin Nutr Metab Care 2012; 15: 392-396.
22. Sullivan JS, Le MT, Pan Z, et al. Oral fructose absorption in obese children with nonalcoholic fatty liver disease. Pediatr Obes 2014; 10: 188-195.
23. Jin R, Le NA, Liu S, et al. Children with nafld are more sensitive to the adverse metabolic effects of fructose beverages than children without nafld. J Clin Endocrinol Metab 2012; 97: E1088-E1098.
24. Moore JB, Gunn PJ, Fielding BA. The role of dietary sugars and de novo lipogenesis in nonalcoholic fatty liver disease. Nutrients 2014; 6: 5679-5703.
25. Cox CL, Stanhope KL, Schwarz JM, et al. Consumption of fructose-sweetened beverages for 10 weeks reduces net fat oxidation and energy expenditure in overweight/obese men and women. Eur J Clin Nutr 2012; 66: 201-208.
26. Crescenzo R, Bianco F, Coppola P, et al. Fructose supplementation worsens the deleterious effects of short-Term high-fat feeding on hepatic steatosis and lipid metabolism in adult rats. Exp Physiol 2014; 99: 1203-1213.
27. Stanhope KL, Havel PJ. Fructose consumption: Recent results and their potential implications. Ann N Y Acad Sci 2010; 1190: 15-24.
28. Stanhope KL, Bremer AA, Medici V, et al. Consumption of fructose and high fructose corn syrup increase postprandial triglycerides, ldl-cholesterol, and apolipoprotein-b in young men and women. J Clin Endocrinol Metab 2011; 96: E1596-1605.
29. Stanhope KL, Schwarz JM, Keim NL, et al. Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans. J Clin Invest 2009; 119: 1322-1334.
30. Pollock NK, Bundy V, Kanto W, et al. Greater fructose consumption is associated with cardiometabolic risk markers and visceral adiposity in adolescents. J Nutr 2012; 142: 251-257.
31. Robubi A, Huber KR, Krugluger W. Extra fructose in the growth medium fuels lipogenesis of adipocytes. J Obes 2014; 2014: 647034.
32. Lim JS, Mietus-Snyder M, Valente A, et al. The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome. Nat Rev Gastroenterol Hepatol 2010; 7: 251-264.
33. Birkenfeld AL, Shulman GI. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology 2014; 59: 713-723.
34. Byrne CD, Targher G. Ectopic fat, insulin resistance, and nonalcoholic fatty liver disease: Implications for cardiovascular disease. Arterioscler Thromb Vasc Biol 2014; 34: 1155-1161.
35. Aeberli I, Hochuli M, Gerber PA, et al. Moderate amounts of fructose consumption impair insulin sensitivity in healthy young men: A randomized controlled trial. Diabetes Care 2013; 36: 150-156.
36. Thorn SR, Baquero KC, Newsom SA, et al. Early life exposure to maternal insulin resistance has persistent effects on hepatic NAFLD in juvenile nonhuman primates. Diabetes 2014; 63: 2702-2713.
37. Patel KR, White FV, Deutsch GH. Hepatic steatosis is prevalent in stillborns delivered to women with diabetes mellitus. J Pediatr Gastroenterol Nutr 2015; 60: 152-158.
38. Sloboda DM, Li M, Patel R, et al. Early life exposure to fructose and offspring phenotype: Implications for long term metabolic homeostasis. J Obes 2014; 2014: 203474.
39. Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology 2014; 146: 1513-1524.
40. Giorgio V, Miele L, Principessa L, et al. Intestinal permeability is increased in children with nonalcoholic fatty liver disease, and correlates with liver disease severity. Dig Liver Dis 2014; 46: 556-560.
41. Miele L, Valenza V, La Torre G, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49: 1877-1887.
42. Vos MB. Nutrition, nonalcoholic fatty liver disease and the microbiome: Recent progress in the field. Curr Opin Lipidol 2014; 25: 61-66.
43. Jin R, Willment A, Patel SS, et al. Fructose induced endotoxemia in pediatric nonalcoholic fatty liver disease. Int J Hepatol 2014; 2014: 560620.